Amerigroup generally does not cover Wegovy when it is prescribed for weight loss. Its Medicaid managed care benefits exclude weight-loss drugs outright, and Wegovy is classified as a weight-loss medication under that rule.1Wellpoint Provider News. Glucagon-Like Peptide-1 Prior Authorization Changes Coverage can open up, however, when the prescription is tied to a different FDA-approved indication, when the member is a child, or when the member lives in a state whose Medicaid program has chosen to pay for obesity drugs.
Why the Default Answer Is No
Amerigroup, which now operates as Wellpoint in several states, states in its pharmacy policies that member benefits “specifically exclude weight loss drugs,” and it identifies Wegovy and Saxenda as medications “FDA-approved for weight loss only and not for treatment of diabetes.”1Wellpoint Provider News. Glucagon-Like Peptide-1 Prior Authorization Changes The exclusion comes from federal law. Under the Medicaid Drug Rebate Program, states are not required to cover drugs prescribed for weight loss, and CMS treats this as an explicit carve-out.2KFF. Medicaid Coverage of and Spending on GLP-1s Because Amerigroup operates as a Medicaid managed care organization, its formulary tracks whatever each state’s Medicaid program allows. Amerigroup’s Iowa prior authorization form puts it plainly: requests for weight loss “will be denied.”3Amerigroup Provider. Anti-Diabetic Non-Insulin Agents Prior Authorization Form
Diagnoses That Can Unlock Coverage
The exclusion applies to Wegovy when the goal of treatment is weight loss. Wegovy has picked up additional FDA-approved indications, and those can qualify for coverage even inside a plan that otherwise bars weight-loss drugs.
Cardiovascular risk reduction. Since March 2024, Wegovy has been approved to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity. New Jersey Medicaid, for example, covers Wegovy “when clinically appropriate for cardiovascular disease.”4NJ Department of Human Services. GLP-1 Coverage Memo In Texas, Wellpoint’s Medicaid prior authorization form sets out the pathway: the patient must be at least 45 years old, carry a diagnosis of cardiovascular disease and obesity or overweight within the past two years, and have tried and failed a preferred formulary alternative. The requested dose cannot exceed four pens per 28 days.5Wellpoint. Prior Authorization of Benefits Form for Wegovy (Texas)
Metabolic dysfunction-associated steatohepatitis (MASH). Amerigroup’s Georgia Medicaid plan sets a quantity limit for Wegovy restricted to patients with a cardiovascular or MASH indication, which means the drug is available on formulary for those diagnoses.6Amerigroup Provider News. Quarterly Pharmacy Formulary Change Notice
Patients under 21. Federal Medicaid law requires coverage of medically necessary treatments for children through the Early and Periodic Screening, Diagnostic and Treatment benefit. Pediatric patients may qualify for GLP-1 coverage for obesity even when adult coverage is excluded.7Pennsylvania Health Law Project. PA Medicaid Ends Adult Coverage of GLP-1s for Weight Loss
Your State Decides as Much as Your Plan Does
Amerigroup and Wellpoint operate Medicaid managed care plans in Georgia (as Amerigroup) and in Washington, D.C., Iowa, New Jersey, Tennessee, Texas, and Washington state (as Wellpoint).8Amerigroup. Amerigroup Medicaid Each sets its own rules on weight-loss drugs.
As of January 2026, only 13 state Medicaid programs cover GLP-1 drugs for obesity treatment at all, and the list has been shrinking. California, New Hampshire, Pennsylvania, and South Carolina recently dropped coverage; North Carolina reinstated it in December 2025.2KFF. Medicaid Coverage of and Spending on GLP-1s North Carolina’s reinstated policy makes Wegovy the preferred product, available with prior authorization, while Zepbound requires trying Wegovy first.9NC Medicaid. NC Medicaid Reinstitute Coverage of GLP-1s for Weight Management
New Jersey’s NJ FamilyCare does not currently cover weight-loss drugs for obesity treatment; the state projected roughly $37.7 million in net state spending for a single fiscal year if it did.4NJ Department of Human Services. GLP-1 Coverage Memo Iowa’s Wellpoint plan excludes Wegovy for weight loss and covers GLP-1s only for type 2 diabetes with documented clinical criteria, such as an A1C of 6.5% or higher.10Wellpoint Provider News. Glucagon-Like Peptide-1 Prior Authorization Changes (Iowa)
Medicare Advantage and Marketplace Members
For Amerigroup Medicare Advantage members, Medicare Part D has historically excluded weight-loss drugs, and the company’s Medicare Advantage policies follow that rule, requiring a verified type 2 diabetes diagnosis before approving any GLP-1.1Wellpoint Provider News. Glucagon-Like Peptide-1 Prior Authorization Changes In April 2025, the Trump administration declined to finalize a Biden-era proposal that would have allowed broader Medicare coverage of obesity drugs.11Georgetown University CHIR. Policy Options to Cover Anti-Obesity Drugs On the ACA Marketplace, a 2024 KFF analysis found that only 1% of plans covered Wegovy, and every plan that did required prior authorization.12KFF. Costly GLP-1 Drugs Are Rarely Covered for Weight Loss by Marketplace Plans
Federal Programs Launching in 2026 and 2027
Two new federal programs may change the answer for some Amerigroup and Wellpoint members.
Starting July 1, 2026, the Medicare GLP-1 Bridge program will give Medicare Advantage members with drug coverage a new pathway to Wegovy for weight management. Members must be 18 or older and meet a BMI threshold: 35 or higher, 30 to 34.99 with qualifying conditions, or 27 to 29.99 with qualifying conditions. The monthly copay is $50 per one-month supply, and the prescriber must certify participation in a diet-and-exercise lifestyle program. The authorization runs through December 31, 2027, and members who already have GLP-1 coverage through their Part D plan are not eligible.13Medicare.gov. Weight-Loss Drugs
On the Medicaid side, the CMS BALANCE model is scheduled to launch in May 2026. It negotiates lower prices for GLP-1 drugs, including Wegovy, Ozempic, Mounjaro, Zepbound, and Rybelsus, for participating state Medicaid programs. Participation is voluntary for states, manufacturers, and health plans, and CMS had not disclosed enrolled states as of early 2026. A Medicare Part D component of BALANCE is set to follow in January 2027.14CMS. BALANCE Model Separately, Medicare drug price negotiations under the Inflation Reduction Act produced a negotiated price of roughly $385 for a 30-day supply of Wegovy, effective January 1, 2027.15Bloomberg Law. Ozempic, Wegovy Medicare Prices Muddled by Trump’s Dueling Deals
If Your Prescription Is Denied
Start with the diagnosis on the prior authorization. If you have established cardiovascular disease, MASH, or another covered indication alongside obesity, your prescriber can resubmit under that diagnosis rather than weight loss. Novo Nordisk’s own guidance confirms that even when a plan treats obesity as an excluded benefit, coverage may still be available when the submission focuses on cardiovascular risk reduction.16Novo Nordisk. Initiating Wegovy Prior Authorization
If the denial stands, file an appeal. Wellpoint sends a Notice of Adverse Determination explaining the reason and your right to appeal, and you can designate a representative, including a doctor or attorney, to handle it. Grievances can be filed through the Wellpoint member portal, mobile app, or by fax.17Wellpoint. Complaints and Grievances
Finally, look at manufacturer self-pay options. Novo Nordisk’s NovoCare sets the self-pay price at $149 per month for the 1.5 mg and 4 mg injection doses through August 31, 2026, with a limited-time introductory rate of $199 per month for the first two fills of starter doses.18Novo Nordisk. Wegovy Savings Card One important limit: patients enrolled in Medicaid, Medicare, VA, or other government programs cannot use the commercial copay savings card. The self-pay option is available, but those costs cannot be submitted for government reimbursement. Without any coverage, Wegovy’s retail price runs about $1,349 per month.19Medical News Today. Wegovy Cost
For most Amerigroup and Wellpoint members, the practical answer today is that Wegovy is covered only when the prescription attaches to something other than weight management, or when the member’s state Medicaid program has specifically opted in. The federal changes arriving in 2026 and 2027 may widen that door, but they will not change the default rule inside most current plans.